Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
Antoniotti C, Marmorino F, Boccaccino A, Martini S, Antista M, Rossini D, Zuco V, Prisciandaro M, Conca V, Zucchelli G, Borelli B, Cosentino P, Germani MM, Bosco MF, Carullo M, Vetere G, Moretto R, Giordano M, Masi G, Pietrantonio F, Zaffaroni N, Cremolini C.
Antoniotti C, et al. Among authors: zuco v.
Eur J Cancer. 2022 Apr;165:116-124. doi: 10.1016/j.ejca.2022.01.025. Epub 2022 Feb 26.
Eur J Cancer. 2022.
PMID: 35231767